Hydroxychloroquine . sulfate
| Code | Size | Price |
|---|
| AG-CR1-3720-M050 | 50 mg | £45.00 |
Quantity:
| AG-CR1-3720-M250 | 250 mg | £130.00 |
Quantity:
| AG-CR1-3720-G001 | 1 g | £190.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
2-[[4-[(7-Chloro-4-quinolinyl)amino]pentyl]ethylamino]-ethanol monosulfate; HCQ; NSC 4375
Appearance:
White to off-white solid.
CAS:
747-36-4
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H302, H315, H319
InChi:
InChI=1S/C18H26ClN3O.H2O4S/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18;1-5(2,3)4/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21);(H2,1,2,3,4)
InChiKey:
JCBIVZZPXRZKTI-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 747-36-4. Formula: C18H26ClN3O . H2SO4. MW: 335.9 . 98.1. Hydroxychloroquine is a synthetic less toxic derivative of chloroquine (Prod. No. AG-CR1-3721), commonly used as an antimalarial drug. Hydroxychloroquine has anti-inflammatory, immunomodulating, anti-infective, antiviral, antithrombotic and metabolic effects. It has anticancer properties, related to their strong antiproliferative, antimutagenic, epigenetic and autophagy inhibiting and apoptosis inducing activities. Hydroxychloroquine is used to treat rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid antibody syndrome and Sj?gren's syndrome. Hydroxychloroquine interfers with lysosomal activity and autophagy, interacts with membrane stability and alters signaling pathways and transcriptional activity, which can result in inhibition of cytokine production and modulation of certain co-stimulatory molecules. It increases lysosomal pH in antigen-presenting cells and blocks in inflammatory conditions, toll-like receptors on plasmacytoid dendritic cells (PDCs). By decreasing TLR signaling, it reduces the activation of dendritic cells and the inflammatory process. It also acts as an antagonist TLR7 and TLR9. Hydroxychloroquine shows antiviral activity against several viruses by inhibiting viral replication and inhibits SARS-CoV-2 viral infection (COVID-19), in vitro.
MDL:
MFCD00078203
Molecular Formula:
C18H26ClN3O . H2SO4
Molecular Weight:
335.9 . 98.1
Package Type:
Vial
Precautions:
P264, P280, P301+P312+P330, P302+352, P305+351+338, P501
Product Description:
Hydroxychloroquine is a synthetic less toxic derivative of chloroquine (Prod. No. AG-CR1-3721), commonly used as an antimalarial drug. Hydroxychloroquine has anti-inflammatory, immunomodulating, anti-infective, antiviral, antithrombotic and metabolic effects. It has anticancer properties, related to their strong antiproliferative, antimutagenic, epigenetic and autophagy inhibiting and apoptosis inducing activities. Hydroxychloroquine is used to treat rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid antibody syndrome and Sj?gren's syndrome. Hydroxychloroquine interfers with lysosomal activity and autophagy, interacts with membrane stability and alters signaling pathways and transcriptional activity, which can result in inhibition of cytokine production and modulation of certain co-stimulatory molecules. It increases lysosomal pH in antigen-presenting cells and blocks in inflammatory conditions, toll-like receptors on plasmacytoid dendritic cells (PDCs). By decreasing TLR signaling, it reduces the activation of dendritic cells and the inflammatory process. It also acts as an antagonist TLR7 and TLR9. Hydroxychloroquine shows antiviral activity against several viruses by inhibiting viral replication and inhibits SARS-CoV-2 viral infection (COVID-19), in vitro.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
ClC1=CC=C(C(NC(CCCN(CC)CCO)C)=CC=N2)C2=C1.O=S(O)(O)=O
Solubility Chemicals:
Soluble in water (20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Inhibition of macroautophagy triggers apoptosis: P. Boya, et al.; Mol. Cell Biol. 25, 1025 (2005) | New insights into the antiviral effects of chloroquine: A. Savarino, et al.; Lancet Infect. Dis. 6, 67 (2006) | Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts: B. Ramser, et al.; J. Invest. Dermatol. 129, 2419 (2009) | Current and novel therapeutics in the treatment of systemic lupus erythematosus: C. Yildirim-Toruner & B. Diamond; J. Allergy Clin. Immunol. 127, 303 (2011) | Hydroxychloroquine: From malaria to autoimmunity: I. Ben-Zvi, et al.; Clin. Rev. Allergy Immunol. 42, 145 (2012) | Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo: M. Lamphier, et al.; Mol. Pharmacol. 85, 429 (2014) | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review: D. Plantone & T. Koudriavtseva; Clin. Drug Investig. 38, 653 (2018) (Review) | The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis: R. Xu, et al.; Medicine 97, e12912 (2018) (Review) | A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine: R. Catalano, et al.; Eur. J. Med. Chem. 183, 111715 (2019) | Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro: J. Liu, et al.; Cell Discov. 6, 16 (2020) | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology: E. Schrezenmeier & T. Dorner; Nat. Rev. Rheumatol. 16, 155 (2020) (Review) | To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic: F.R. Spinelli, et al.; Ann. Rheum. Dis. (Epub ahead of print) (2020) | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? C.A. Devaux, et al.; Int. J. Antimicrob. Agents. (Epub ahead of print) (2020)